{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T22:00:59Z","timestamp":1774821659786,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.pharma.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T09:08:22Z","timestamp":1704964102000},"page":"392-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chronic kidney disease in America, Africa, and Asia: Overview of treatment cost and options"],"prefix":"10.1016","volume":"82","author":[{"given":"Rania","family":"Mourchid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Bellahcen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahia","family":"Cherrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Serragui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2024.01.002_bib0380","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12325-021-01927-z","article-title":"A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives","volume":"39","author":"Marc","year":"2022","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.pharma.2024.01.002_bib0385","doi-asserted-by":"crossref","first-page":"e038401","DOI":"10.1136\/bmjopen-2020-038401","article-title":"Associations between multimorbidity and adverse clinical outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"10","author":"Sullivan","year":"2020","journal-title":"BMJ Open"},{"issue":"9836","key":"10.1016\/j.pharma.2024.01.002_bib0390","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharma.2024.01.002_bib0410","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13814789609162146","article-title":"Comorbidity or multimorbidity: what's in a name? A review of literature","volume":"2","author":"Van den Akker","year":"1996","journal-title":"Eur J Gen Pract"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.002_bib0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Kovesdy Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Csaba","year":"2022","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"10.1016\/j.pharma.2024.01.002_bib0395","doi-asserted-by":"crossref","first-page":"743","DOI":"10.5124\/jkma.2014.57.9.743","article-title":"Management of multimorbidity in the elderly","volume":"57","author":"Kim","year":"2014","journal-title":"J Korean Med Assoc"},{"key":"10.1016\/j.pharma.2024.01.002_bib0400","series-title":"Health reform: meeting the challenge of aging and multiple morbidities.","first-page":"22","year":"2011"},{"key":"10.1016\/j.pharma.2024.01.002_bib0430","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrneph.2015.25","article-title":"Epidemiology: spotlight on CKD deaths-increasing mortality worldwide","volume":"11","author":"Rhee","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharma.2024.01.002_bib0425","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Mortality causes of death collaborators global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharma.2024.01.002_bib0435","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"issue":"704","key":"10.1016\/j.pharma.2024.01.002_bib0440","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.3399\/bjgp20X714125","article-title":"Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care","volume":"71","author":"MacRae","year":"2021","journal-title":"Br J Gen Pract"},{"issue":"12","key":"10.1016\/j.pharma.2024.01.002_bib0445","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/jcm7120493","article-title":"The number of comorbidities predicts renal outcomes in patients with stage 3\u20135 chronic kidney disease","volume":"7","author":"Lee","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharma.2024.01.002_bib0450","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12882-015-0189-z","article-title":"The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study Fraser et al","volume":"16","author":"Fraser","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharma.2024.01.002_bib0455","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.pharma.2024.01.002_bib0460","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-016-1363-8","article-title":"Mineral metabolism and cardiovascular disease in CKD","volume":"21","author":"Fujii","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.pharma.2024.01.002_bib0420","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharma.2024.01.002_bib0465","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12882-015-0189-z","article-title":"The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study Fraser et al.","volume":"16","author":"Fraser","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharma.2024.01.002_bib0475","volume":"360","author":"Craig","year":"2020"},{"key":"10.1016\/j.pharma.2024.01.002_bib0470","series-title":"Nearly half of U.S. adults have high blood pressure by Alicia Rohan","year":"2019"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.002_bib0490","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhealeco.2011.10.003","article-title":"The medical care costs of obesity: an instrumental variables approach","volume":"31","author":"Cawley","year":"2012","journal-title":"J Health Econ"},{"key":"10.1016\/j.pharma.2024.01.002_bib0480","article-title":"Nearly half of all adult Americans have cardiovascular disease","year":"2019","journal-title":"ScienceDaily"},{"key":"10.1016\/j.pharma.2024.01.002_bib0485","unstructured":"Elisa Resources. The cost of Chronic Kidney Disease (CKD) https:\/\/www.ethosbiosciences.com\/the-cost-of-chronic-kidney-disease-ckd."},{"key":"10.1016\/j.pharma.2024.01.002_bib0495","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. About multiple causes of death, 1999\u20132020. CDC WONDER Online Database website. Atlanta 2023 (lastest review)."},{"key":"10.1016\/j.pharma.2024.01.002_bib0500","series-title":"Chronic kidney disease in the United States","year":"2021"},{"key":"10.1016\/j.pharma.2024.01.002_bib0505","series-title":"2020 USRDS annual data report: epidemiology of kidney disease in the United States","year":"2020"},{"issue":"3","key":"10.1016\/j.pharma.2024.01.002_bib0510","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5935\/0101-2800.20170049","article-title":"Brazilian chronic dialysis survey 2016","volume":"39","author":"Sesso","year":"2017","journal-title":"J Bras Nefrol"},{"issue":"8","key":"10.1016\/j.pharma.2024.01.002_bib0515","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1590\/S0102-311X2010000800016","article-title":"Determinantes dos gastos com di\u00e1lises no Sistema \u00danico de Sa\u00fade, Brasil, 2000 a 2004","volume":"26","author":"Cherchiglia","year":"2010","journal-title":"Cad Saude Publica"},{"issue":"10","key":"10.1016\/j.pharma.2024.01.002_bib0520","doi-asserted-by":"crossref","first-page":"e0203992","DOI":"10.1371\/journal.pone.0203992","article-title":"Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System","volume":"13","author":"Goncalves","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2024.01.002_bib0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2215\/CJN.12391211","article-title":"A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease","volume":"7","author":"Manns","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.pharma.2024.01.002_bib0530","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.120833","article-title":"Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey","volume":"185","author":"Arora","year":"2013","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.pharma.2024.01.002_bib0535","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/ajkd.2002.34924","article-title":"Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access","volume":"40","author":"Lee","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharma.2024.01.002_bib0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2054358119835521","article-title":"The cost of care for people with chronic kidney disease","volume":"6","author":"Manns","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.pharma.2024.01.002_bib0545","series-title":"Public private partnership manual","year":"2004"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.002_bib0550","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12913-015-1166-8","article-title":"The cost of dialysis in low and middle-income countries: a systematic review","volume":"15","author":"Mushi","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.002_bib0555","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3747\/pdi.2008.00226","article-title":"Peritoneal dialysis in Africa","volume":"30","author":"Abu-Aisha","year":"2010","journal-title":"Perit Dial Int"},{"issue":"8","key":"10.1016\/j.pharma.2024.01.002_bib0560","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7196\/SAMJ.2019.v109i8.13597","article-title":"An analysis of the direct cost of renal dialysis provided through a public-private partnership at a tertiary hospital in Limpopo Province","volume":"109","author":"Malatji","year":"2019","journal-title":"S Afr Med J"},{"key":"10.1016\/j.pharma.2024.01.002_bib0565","unstructured":"Strat\u00e9gie nationale multisectorielle de pr\u00e9vention et de contr\u00f4le des maladies non transmissibles 2019\u20132029."},{"key":"10.1016\/j.pharma.2024.01.002_bib0570","doi-asserted-by":"crossref","unstructured":"M Asserraji, G Dohmi, N Abdelbaki. Co\u00fbt de l\u2019h\u00e9modialyse au Maroc -nephro.2016.07.342.","DOI":"10.1016\/j.nephro.2016.07.342"},{"issue":"12","key":"10.1016\/j.pharma.2024.01.002_bib0575","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/13696998.2016.1207653","article-title":"A societal cost-of-illness study of hemodialysis in Lebanon","volume":"19","author":"Rizk","year":"2016","journal-title":"J Med Econ"},{"issue":"10","key":"10.1016\/j.pharma.2024.01.002_bib0580","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/13696998.2016.1221830","article-title":"Dialysis: the best quality at the lowest cost","volume":"19","author":"Aoun","year":"2016","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.pharma.2024.01.002_bib0585","doi-asserted-by":"crossref","first-page":"134","DOI":"10.26719\/emhj.18.032","article-title":"Ultrapure water in haemodialysis: a step towards better quality in Lebanon","volume":"25","author":"Aoun","year":"2019","journal-title":"East Mediterr Health J"},{"issue":"2","key":"10.1016\/j.pharma.2024.01.002_bib0590","doi-asserted-by":"crossref","first-page":"89","DOI":"10.12816\/0054122","article-title":"Prevalence of chronic kidney disease in an outpatient setting","volume":"67","author":"Aoun","year":"2019","journal-title":"Lebanese Med J"},{"issue":"10225","key":"10.1016\/j.pharma.2024.01.002_bib0595","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2024.01.002_bib0600","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","article-title":"Cost-of-illness studies: concepts, scopes, and methods","volume":"20","author":"Jo","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"10.1016\/j.pharma.2024.01.002_bib0605","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1590\/1806-9282.64.12.1108","article-title":"Global costs attributed to chronic kidney disease: a systematic review","volume":"64","author":"Da Silva","year":"2018","journal-title":"Rev Assoc Med Bras"},{"issue":"4","key":"10.1016\/j.pharma.2024.01.002_bib0610","doi-asserted-by":"crossref","first-page":"e0231375","DOI":"10.1371\/journal.pone.0231375","article-title":"Costs of patients with chronic kidney disease in Germany","volume":"15","author":"Gandjour","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2024.01.002_bib0615","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10198-016-0830-1","article-title":"The social cost of chronic kidney disease in Italy","volume":"18","author":"Turchetti","year":"2017","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.pharma.2024.01.002_bib0620","doi-asserted-by":"crossref","first-page":"e036317","DOI":"10.1136\/bmjopen-2019-036317","article-title":"Healthcare utilisation and expenditure patterns for cardio-metabolic diseases in South Asian cities: the CARRS Study","volume":"10","author":"Gupta","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.pharma.2024.01.002_bib0625","doi-asserted-by":"crossref","first-page":"e0230512","DOI":"10.1371\/journal.pone.0230512","article-title":"The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review","volume":"15","author":"Elshahat","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.002_bib0630","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12913-020-4974-4","article-title":"The societal economic burden of autosomal dominant polycystic kidney disease in the United States","volume":"20","author":"Cloutier","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.pharma.2024.01.002_bib0635","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5414\/CNP92S117","article-title":"Monthly direct and indirect costs of management of CKD 3-5 non-dialysis patients in an out-of-pocket expenditure system: the Case of Yaound\u00e9","volume":"93","author":"Ngeugoue","year":"2020","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.pharma.2024.01.002_bib0640","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/ndt\/gfm939","article-title":"Reimbursement and economic factors influencing dialysis modality choice around the world","volume":"23","author":"Just","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2024.01.002_bib0645","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/s12913-022-07936-0","article-title":"Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives","volume":"22","author":"Aoun","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.pharma.2024.01.002_bib0650","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/0973-3930.43101","article-title":"Epidemiology of chronic kidney disease in a Sri Lankan population","volume":"28","author":"Gooneratne","year":"2008","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.pharma.2024.01.002_bib0655","unstructured":"World Health Organization Sri Lanka: chronic kidney disease of unknown aetiology (CKDu): a new threat to health."},{"key":"10.1016\/j.pharma.2024.01.002_bib751","doi-asserted-by":"crossref","unstructured":"Ranasinghe P, Perera YS, Makarim MF, Wijesinghe A, Wanigasuriya K. The costs in provision of haemodialysis in a developing country: a multi-centered study. BMC Nephrol. 2011 Sep 6;12:42. doi: 10.1186\/1471-2369-12-42. PMID: 21896190; PMCID: PMC3189097.","DOI":"10.1186\/1471-2369-12-42"},{"issue":"5","key":"10.1016\/j.pharma.2024.01.002_bib0660","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/ndt\/gfp669","article-title":"Prevalence and risk factors of chronic kidney disease in the Thai adult population: thai SEEK study","volume":"25","author":"Ingsathit","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2024.01.002_bib0685","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/CEOR.S253252","article-title":"Treatment costs for patients with chronic kidney disease who received multidisciplinary care in a district hospital in Thailand","volume":"12","author":"Songsermlosakul","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.pharma.2024.01.002_bib0690","series-title":"The cost of dialysis","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0695","series-title":"The cost of dialysis in Canada","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0700","series-title":"The cost of dialysis in Thailand","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0705","series-title":"The cost of dialysis in Brazil","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0710","series-title":"The cost of dialysis in Morocco","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0715","series-title":"The cost of dialysis in Sri Lanka","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0720","series-title":"The cost of dialysis in South Africa","year":"2022"},{"key":"10.1016\/j.pharma.2024.01.002_bib0725","series-title":"The cost of dialysis in Lebanon","year":"2022"},{"issue":"8","key":"10.1016\/j.pharma.2024.01.002_bib0730","first-page":"e1000444","article-title":"Worldwide burden of chronic kidney disease in 2013: estimates from a model-based approach","volume":"10","author":"Lee","year":"2013","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.pharma.2024.01.002_bib0735","first-page":"1727","article-title":"Association of adult body mass index with chronic kidney disease: a systematic review and meta-analysis","volume":"33","author":"Soni","year":"2018","journal-title":"Nephrol Dialysis Transpl"},{"key":"10.1016\/j.pharma.2024.01.002_bib0740","series-title":"Diabetes and chronic kidney disease","year":"2023"},{"key":"10.1016\/j.pharma.2024.01.002_bib0745","series-title":"Chronic Kidney Disease (CKD) in diabetes","year":"2023"},{"key":"10.1016\/j.pharma.2024.01.002_bib0750","series-title":"World health statistics","year":"2023"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T20:12:03Z","timestamp":1713298323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0003450924000026"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.01.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic kidney disease in America, Africa, and Asia: Overview of treatment cost and options","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}